Click HERE to register for a LIVE presentation from industry expert Ned Wakeman on A New Shared-risk Partnership Model for Developing and Commercializing Oncology Innovations.
Developing and commercialising new oncology medicines, biomarkers and models requires a multi-disciplinary, collaborative approach and has historically been conducted by large Pharma companies. The closure of Pharma sites in the UK has reduced oncology R&D activity and has fragmented the expertise and know-how, which was historically contained within these large companies. This was evidenced at Alderley Park, where the relocation of AstraZeneca’s (AZ) main R&D site to Cambridge (but only a small portion of its staff) has resulted in a concentration of scientists with oncology R&D expertise in the area, many of whom have established start-up businesses or have joined existing companies or academic research groups. This has bolstered the pre-existing oncology research community in the Manchester area, which includes the Christie Hospital and a number of world-class oncology research centres with a focus on basic and translational research and oncology drug discovery. In parallel, Alderley Park has developed into a leading hub for the creation and nurturing of life-science start-up companies (86 spinouts from AZ, over 240 expert mentors, 60 consultants), with high-quality lab space and support facilities, Contract Research Organisations (CROs) and established start-up creation and development programmes. In addition, the recent creation of the Medicines Discovery Catapult at Alderley Park has provided specialist capabilities designed to address the needs of the drug discovery community across the UK. Taken together, and collaborting with industry, these developments in the Manchester/Alderley Park area provide a unique opportunity in the UK to establish new collaborative, capital efficient shared-risk models of drug discovery and development, in order to create new companies, de-risk, and catalyse the transition of new medicines and other clinically meaningful products to market.